Skip to main content
Loading

Leverna Therapeutics

October 18, 2023
Franciscan B
CNS/Neurological
Company Description: LEVERaging RNA regulatory mechanisms to drug the undruggable with RNA-targeted therapeutics. We identify novel target RNA biology and design targeted therapeutics to increase, inhibit or restore expression/protein function. We currently have 4 programs in CNS and related disease areas, with the lead program (L5001) going into IND in 2025.
Speakers
Avery (Qinghong) Yan, Co-Founder, President & CSO - Leverna Therapeutics